Q-omics provides the consensus-scored FAM135A profile across patient tissues and cancer cell-line models. FAM135A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM135A is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, FAM135A RNA expression shows 20,654 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where FAM135A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM135A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM135A survival associations across molecular data types. FAM135A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM135A RNA expression–survival associations across cancer types. High FAM135A expression shows unfavorable associations in STAD, but favorable associations in KIRC, SKCM, READ, COAD and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM135A RNA expression.
This table summarizes FAM135A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FAM135A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM135A shows lower tumor expression in THCA and BRCA and higher tumor expression in CHOL, LUSC, LIHC and KICH. The THCA box plot shows higher FAM135A RNA expression in normal versus tumor tissue (log2 FC = −0.352, t-test p < 0.001).
This table shows molecular features associated with FAM135A in patient tissues and cancer cell lines. In patient samples, FAM135A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM135A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
